vidarabine phosphate and Disease Exacerbation

vidarabine phosphate has been researched along with Disease Exacerbation in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's1 (33.33)18.2507
2000's2 (66.67)29.6817
2010's0 (0.00)24.3611
2020's0 (0.00)2.80

Authors

AuthorsStudies
Barbui, T; Coiffier, B; Foran, JM; Hiddemann, W; Johnson, SA; Lister, TA; Norton, AJ; Radford, JA; Rohatiner, AZ; Tollerfield, SM; Wilson, MP1
Autrand, C; Binet, JL; Boudjerra, N; Cazin, B; Chastang, C; Chevret, S; Desablens, B; Dighiero, G; Divine, M; Dreyfus, B; Feugier, P; Jaubert, J; Leporrier, M; Maloum, K; Rapp, MJ; Travade, P1
Binet, JL; Boogaerts, MA; Bosch, F; Catovsky, D; Feremans, W; Klein, M; Kovacs, M; Marcus, R; Montillo, M; Van Hoof, A; Verhoef, G; Zinzani, PL1

Trials

3 trial(s) available for vidarabine phosphate and Disease Exacerbation

ArticleYear
Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenström's macroglobulinemia, and mantle-cell lymphoma.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 1999, Volume: 17, Issue:2

    Topics: Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphoma, Non-Hodgkin; Male; Middle Aged; Survival Analysis; Vidarabine Phosphate; Waldenstrom Macroglobulinemia

1999
Randomized comparison of fludarabine, CAP, and ChOP in 938 previously untreated stage B and C chronic lymphocytic leukemia patients.
    Blood, 2001, Oct-15, Volume: 98, Issue:8

    Topics: Aged; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cisplatin; Cyclophosphamide; Disease Progression; Doxorubicin; Female; Follow-Up Studies; Hospitalization; Humans; Leukemia, Lymphocytic, Chronic, B-Cell; Lymphocyte Count; Male; Middle Aged; Neoplasm Staging; Phosphoramide Mustards; Prednisone; Prognosis; Proportional Hazards Models; Sample Size; Survival Rate; Time Factors; Vidarabine Phosphate; Vincristine

2001
Activity of oral fludarabine phosphate in previously treated chronic lymphocytic leukemia.
    Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 2001, Nov-15, Volume: 19, Issue:22

    Topics: Administration, Oral; Adult; Aged; Antimetabolites, Antineoplastic; Disease Progression; Disease-Free Survival; Drug Evaluation; Female; Humans; Infusions, Intravenous; Leukemia, Lymphocytic, Chronic, B-Cell; Male; Middle Aged; Prospective Studies; Treatment Outcome; Vidarabine Phosphate

2001